{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:53:46Z","timestamp":1787162026741,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s11926-018-0760-2","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T03:04:27Z","timestamp":1529550267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout"],"prefix":"10.1007","volume":"20","author":[{"given":"Garry G.","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie L.","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diluk R.W.","family":"Kannangara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard O.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"issue":"9","key":"760_CR1","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/qjmed\/95.9.597","volume":"95","author":"LD Fairbanks","year":"2002","unstructured":"Fairbanks LD, Cameron JS, Venkat-Raman G, Rigden SP, Rees L, Van THW, et al. Early treatment with allopurinol in familial juvenile hyerpuricaemic nephropathy (FJHN) ameliorates the long-term progression of renal disease. QJM. 2002;95(9):597\u2013607.","journal-title":"QJM"},{"issue":"10","key":"760_CR2","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"760_CR3","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"760_CR4","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46(8):1372\u20134.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"760_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.clinthera.2012.12.011","volume":"35","author":"P Ye","year":"2013","unstructured":"Ye P, Yang S, Zhang W, Lv Q, Cheng Q, Mei M, et al. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. Clin Ther. 2013;35(2):180\u20139.","journal-title":"Clin Ther"},{"issue":"6","key":"760_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273\u201382.","journal-title":"J Rheumatol"},{"issue":"4","key":"760_CR7","first-page":"529","volume":"56","author":"A Abhishek","year":"2017","unstructured":"\u2022 Abhishek A, Jenkins W, La-Crette J, Fernandes G, Doherty M. Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study. Rheumatology (Oxford). 2017;56(4):529\u201333. This paper shows the importance of maintaining good adherence in optimising the clinical response to allopurinol","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"760_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrrheum.2015.132","volume":"12","author":"LK Stamp","year":"2016","unstructured":"Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheumatol. 2016;12(4):235\u201342.","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"760_CR9","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"SI Hung","year":"2005","unstructured":"Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"760_CR10","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/art.34488","volume":"64","author":"LK Stamp","year":"2012","unstructured":"Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529\u201336.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"760_CR11","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, F JD, Khanna PP, Bae S, Singh MK, N T, et al. 2012 American College of Rheumatology Guidelines for Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"760_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"760_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47\u201356.","journal-title":"Am J Med"},{"issue":"10","key":"760_CR14","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/ard.60.10.981","volume":"60","author":"J Vazquez-Mellado","year":"2001","unstructured":"Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. 2001;60(10):981\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"760_CR15","first-page":"1646","volume":"33","author":"N Dalbeth","year":"2006","unstructured":"Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33(8):1646\u201350.","journal-title":"J Rheumatol"},{"issue":"1","key":"760_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/RHU.0b013e318164dceb","volume":"14","author":"D Panomvana","year":"2008","unstructured":"Panomvana D, Sripradit S, Angthararak S. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. J Clin Rheumatol. 2008;14(1):6\u201311.","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"760_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/art.30119","volume":"63","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 2011;63(2):412\u201321.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"760_CR18","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","volume":"76","author":"LK Stamp","year":"2017","unstructured":"\u2022 Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76(9):1522\u20138. This study demonstrated that allopurinol doses titrated to target serum urate concentrations are well tolerated and lower serum urate concentrations more effectively than allopruinol doses based on renal function","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"760_CR19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","volume":"72","author":"F Rees","year":"2013","unstructured":"Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72(6):826\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"760_CR20","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1136\/annrheumdis-2017-211873","volume":"76","author":"LK Stamp","year":"2017","unstructured":"Stamp LK, Chapman PT, Barclay M, Horne A, Frampton C, Tan P, et al. Allopurinol dose escalation to achieve serum urate below 6 mg\/dL: an open-label extension study. Ann Rheum Dis. 2017;76(12):2065\u201370.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"760_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.semarthrit.2014.01.004","volume":"44","author":"CG Jennings","year":"2014","unstructured":"Jennings CG, Mackenzie IS, Flynn R, Ford I, Nuki G, De Caterina R, et al. Up-titration of allopurinol in patients with gout. Semin Arthritis Rheum. 2014;44(1):25\u201330.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"760_CR22","doi-asserted-by":"crossref","first-page":"e017281","DOI":"10.1136\/bmjopen-2017-017281","volume":"7","author":"RO Day","year":"2017","unstructured":"Day RO, Frensham LJ, Nguyen AD, Baysari MT, Aung E, Lau AYS, et al. Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol. BMJ Open. 2017;7(10):e017281.","journal-title":"BMJ Open"},{"key":"760_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijmedinf.2016.06.021","volume":"94","author":"AD Nguyen","year":"2016","unstructured":"Nguyen AD, Baysari MT, Kannangara DR, Tariq A, Lau AY, Westbrook JI, et al. Mobile applications to enhance self-management of gout. Int J Med Inform. 2016;94:67\u201374.","journal-title":"Int J Med Inform"},{"issue":"7","key":"760_CR24","doi-asserted-by":"publisher","first-page":"925","DOI":"10.4065\/81.7.925","volume":"81","author":"CA Sarawate","year":"2006","unstructured":"Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81(7):925\u201334.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"760_CR25","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/rheumatology\/kes431","volume":"52","author":"G Zandman-Goddard","year":"2013","unstructured":"Zandman-Goddard G, Amital H, Shamrayevsky N, Raz R, Shalev V, Chodick G. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel. Rheumatology (Oxford). 2013;52(6):1126\u201331.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"760_CR26","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3899\/jrheum.140588","volume":"42","author":"N Rashid","year":"2015","unstructured":"Rashid N, Coburn BW, Wu YL, Cheetham TC, Curtis JR, Saag KG, et al. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol. 2015;42(3):504\u201312.","journal-title":"J Rheumatol"},{"key":"760_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2147\/CEOR.S139939","volume":"9","author":"R Sheer","year":"2017","unstructured":"Sheer R, Null KD, Szymanski KA, Sudharshan L, Banovic J, Pasquale MK. Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat. Clinicoecon Outcomes Res. 2017;9:629\u201339.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2","key":"760_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3810\/pgm.2014.03.2741","volume":"126","author":"H Hatoum","year":"2014","unstructured":"Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. Postgrad Med. 2014;126(2):65\u201375.","journal-title":"Postgrad Med"},{"issue":"2","key":"760_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00124743-199904000-00003","volume":"5","author":"F Perez-Ruiz","year":"1999","unstructured":"Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erauskin G, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol. 1999;5(2):49\u201355.","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"760_CR30","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/bcp.12126","volume":"76","author":"GG Graham","year":"2013","unstructured":"Graham GG, Kannangara DR, Stocker SL, Portek I, Pile KD, Indraratna PL, et al. Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. Br J Clin Pharmacol. 2013;76(6):932\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"760_CR31","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/annrheumdis-2015-208111","volume":"75","author":"DR Kannangara","year":"2016","unstructured":"Kannangara DR, Phipps-Green AJ, Dalbeth N, Stamp LK, Williams KM, Graham GG, et al. Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate. Ann Rheum Dis. 2016;75(7):1363\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"760_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1159\/000184368","volume":"46","author":"A Garyfallos","year":"1987","unstructured":"Garyfallos A, Magoula I, Tsapas G. Evaluation of the renal mechanisms for urate homeostasis in uremic patients by probenecid and pyrazinamide test. Nephron. 1987;46(3):273\u201380.","journal-title":"Nephron"},{"issue":"2","key":"760_CR33","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/bcp.12799","volume":"81","author":"DF Wright","year":"2016","unstructured":"Wright DF, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK. Predicting allopurinol response in patients with gout. Br J Clin Pharmacol. 2016;81(2):277\u201389.","journal-title":"Br J Clin Pharmacol"},{"issue":"6 Suppl","key":"760_CR34","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/ard.25.Suppl_6.660","volume":"25","author":"A Rapado","year":"1966","unstructured":"Rapado A. Allopurinol in thiazide-induced hyperuricaemia. Ann Rheum Dis. 1966;25(6 Suppl):660\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"760_CR35","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12(2):R63.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"760_CR36","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3899\/jrheum.101160","volume":"38","author":"SL Stocker","year":"2011","unstructured":"Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol. 2011;38(5):904\u201310.","journal-title":"J Rheumatol"},{"issue":"1","key":"760_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/art.39840","volume":"69","author":"KG Saag","year":"2017","unstructured":"Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol. 2017;69(1):203\u201312.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"760_CR38","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1136\/annrheumdis-2015-207919","volume":"75","author":"F Perez-Ruiz","year":"2016","unstructured":"Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C, Group RS. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis. 2016;75(6):1074\u201380.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"760_CR39","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","volume":"26","author":"MK Reinders","year":"2007","unstructured":"Reinders MK, van Roon EN, Houtman PM, Brouwers JR, Jansen TL. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol. 2007;26(9):1459\u201365.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"760_CR40","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1093\/rheumatology\/ket487","volume":"53","author":"R Fleischmann","year":"2014","unstructured":"Fleischmann R, Kerr B, Yeh LT, Suster M, Shen Z, Polvent E, et al. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology (Oxford). 2014;53(12):2167\u201374.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"760_CR41","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/art.40159","volume":"69","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheumatol. 2017;69(9):1903\u201313.","journal-title":"Arthritis Rheumatol"},{"key":"760_CR42","doi-asserted-by":"publisher","first-page":"263720","DOI":"10.1155\/2014\/263720","volume":"2014","author":"VF Azevedo","year":"2014","unstructured":"Azevedo VF, Buiar PG, Giovanella LH, Severo CR, Carvalho M. Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients. Int J Rheumatol. 2014;2014:263720.","journal-title":"Int J Rheumatol"},{"issue":"12","key":"760_CR43","first-page":"1687","volume":"33","author":"W Loffler","year":"1983","unstructured":"Loffler W, Grobner W, Zollner N. Uric acid-lowering effect of a combination of benzbromarone and allopurinol\u2014studies under standardized dietary conditions. Arzneimittelforschung. 1983;33(12):1687\u201391.","journal-title":"Arzneimittelforschung"},{"issue":"5","key":"760_CR44","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/cpt.89","volume":"97","author":"CC Wen","year":"2015","unstructured":"\u2022 Wen CC, Yee SW, Liang X, Hoffmann TJ, Kvale MN, Banda Y, et al. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin Pharmacol Ther. 2015;97(5):518\u201325. The is the first (GWAS) study identifying the ABCG2 transporter as a determinant of response to allopurinol","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"760_CR45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/tpj.2015.101","volume":"17","author":"RL Roberts","year":"2017","unstructured":"\u2022 Roberts RL, Wallace MC, Phipps-Green AJ, Topless R, Drake JM, Tan P, et al. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenom J. 2017;17(2):201\u20133. This study replicates the findings from Wen et al 2015 and demonstrates that the minor allele of rs2231142 is associated with an increased risk of poor response to allopurinol in gouty patients","journal-title":"Pharmacogenom J"},{"issue":"1","key":"760_CR46","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.dmpk.2016.08.003","volume":"32","author":"M Lin","year":"2017","unstructured":"Lin M, Liu J, Zhou H, Wu M, Lv D, Huang Y, et al. Effects of UDP-glucuronosyltransferase (UGT) polymorphisms on the pharmacokinetics of febuxostat in healthy Chinese volunteers. Drug Metab Pharmacokinet. 2017;32(1):77\u201384.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"9","key":"760_CR47","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1111\/bcp.13307","volume":"83","author":"DRW Kannangara","year":"2017","unstructured":"Kannangara DRW, Graham GG, Wright DFB, Stocker SL, Portek I, Pile KD, et al. Individualising the dose of allopurinol in patients with gout. Br J Clin Pharmacol. 2017;83(9):2015\u201326.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-018-0760-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0760-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0760-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T12:43:40Z","timestamp":1720356220000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-018-0760-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["760"],"URL":"https:\/\/doi.org\/10.1007\/s11926-018-0760-2","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,21]]},"assertion":[{"value":"21 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"47"}}